Literature DB >> 21817107

MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities.

Mian Wang1, Wen Li, Guang-Qi Chang, Cai-Sheng Ye, Jing-Song Ou, Xiao-Xi Li, Yong Liu, Tuck-Yun Cheang, Xue-Ling Huang, Shen-Ming Wang.   

Abstract

OBJECTIVE: The goal of this study was to determine the expression signature and the potential role of microRNAs in human arteries with arteriosclerosis obliterans (ASO). METHODS AND
RESULTS: The expression profiles of microRNAs in human arteries with ASO and in normal control arteries were determined by quantitative reverse transcription-polymerase chain reaction array. Among the 617 detected microRNAs, multiple microRNAs were aberrantly expressed in arteries with ASO. Some of these dysregulated microRNAs were further verified by quantitative reverse transcription-polymerase chain reaction. Among them, microRNA-21 (miR-21) was mainly located in arterial smooth muscle cells (ASMCs) and was increased by more than 7-fold in ASO that was related to hypoxia inducible factor 1-α. In cultured human ASMCs, cell proliferation and migration were significantly decreased by inhibition of miR-21. 3'-Untranslated region luciferase assay confirmed that tropomyosin 1 was a target of miR-21 that was involved in miR-21-mediated cellular effects, such as cell shape modulation.
CONCLUSION: The results suggest that miR-21 is able to regulate ASMC function by targeting tropomyosin 1. The hypoxia inducible factor-1 α/miR-21/tropomyosin 1 pathway may play a critical role in the pathogenesis of ASO. These findings might provide a new therapeutic target for human ASO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21817107     DOI: 10.1161/ATVBAHA.111.229559

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  60 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 2.  Vascular Smooth Muscle as a Target for Novel Therapeutics.

Authors:  Karen E Porter; Kirsten Riches
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

3.  Local Anti-miR Delivery: The Latest in the Arsenal of Drug-Eluting Stents.

Authors:  Kathryn J Moore; Katey J Rayner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09       Impact factor: 8.311

4.  MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation.

Authors:  Pan Li; Ni Zhu; Bing Yi; Nadan Wang; Ming Chen; Xiaohua You; Xianxian Zhao; Charalambos C Solomides; Yongwen Qin; Jianxin Sun
Journal:  Circ Res       Date:  2013-09-06       Impact factor: 17.367

5.  MicroRNAs and Cardiovascular Disease.

Authors:  Carlos Fernández-Hernando; Angel Baldán
Journal:  Curr Genet Med Rep       Date:  2013-03

6.  Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Effectively Prevents Experimental In-Stent Restenosis.

Authors:  Dong Wang; Tobias Deuse; Mandy Stubbendorff; Ekaterina Chernogubova; Reinhold G Erben; Suzanne M Eken; Hong Jin; Yuhuang Li; Albert Busch; Christian-H Heeger; Boris Behnisch; Hermann Reichenspurner; Robert C Robbins; Joshua M Spin; Philip S Tsao; Sonja Schrepfer; Lars Maegdefessel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-07-16       Impact factor: 8.311

Review 7.  OxymiRs in cutaneous development, wound repair and regeneration.

Authors:  Chandan K Sen; Sashwati Roy
Journal:  Semin Cell Dev Biol       Date:  2012-10-10       Impact factor: 7.727

Review 8.  Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease.

Authors:  Naomi M Hamburg; Nicholas J Leeper
Journal:  Curr Vasc Pharmacol       Date:  2015       Impact factor: 2.719

9.  Therapeutic Potential of Modulating microRNAs in Atherosclerotic Vascular Disease.

Authors:  Elisa Araldi; Aranzazu Chamorro-Jorganes; Coe van Solingen; C Fernández-Hernando; Y Suárez
Journal:  Curr Vasc Pharmacol       Date:  2013-05-13       Impact factor: 2.719

10.  MiR-142-3p attenuates the migration of CD4⁺ T cells through regulating actin cytoskeleton via RAC1 and ROCK2 in arteriosclerosis obliterans.

Authors:  Jiawei Liu; Wen Li; Siwen Wang; Yidan Wu; Zilun Li; Wenjian Wang; Ruiming Liu; Jingsong Ou; Chunxiang Zhang; Shenming Wang
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.